Non-oral delivery systems in headache therapy: Focus on intranasal delivery

American Journal of Drug Delivery

Volumn 2, Issue 1, 2004, Pages 59-68

  Limmroth, Volker ^a   Dowson, Andrew J ^b   Diener, Hans Christoph ^a   Dahlöf, Carol ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c Gothenburg Migraine Clinic   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; DIHYDROERGOTAMINE MESILATE; DONITRIPTAN; ELETRIPTAN; ERGO MEDIHALER; ERGOTAMINE; ERGOTAMINE TARTRATE; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ABDOMINAL PAIN; ANGINA PECTORIS; ANXIETY; AREA UNDER THE CURVE; CLINICAL TRIAL; CLUSTER HEADACHE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL ABSORPTION; HUMAN; MIGRAINE; MYALGIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN TINGLING; SUPPOSITORY; TASTE DISORDER; TEMPERATURE SENSITIVITY; VASOCONSTRICTION; VOMITING;

EID: 2942514882     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200402010-00004     Document Type: Review

References (59)

1. Dahlöf CGH. Characteristics of different routes of administration. In: Olesen J, Ferrari M, Humphrey PPA, editors, Frontiers in headache research: the triptans: novel drugs for migraine. Oxford: Oxford University Press, 2001: 80-90
2. Volans GN. The absorption of effervesent aspirin in migraine. BMJ 1974; 4: 265-8
3. Tokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol 1984; 18: 867-71
4. Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975; 2: 75-63
5. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984; 4: 107-11
6. Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984; 17: 67-75
7. MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993; 13: 124-7
8. Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 2002; 1: 251-7
9. Dahlöf C. Integrating the triptans into clinical practice. Curr Opin Neurol 2002; 15: 317-22
10. Eulenberg A. Subcutane injectionen von ergotamin (Tantret): ergotamin citricum solutum (Gehe). Dtsch Med Wochenschr 1883; 9: 637-9
11. Dahlöf C, Goadsby P. Ergots: therapy. In: Diener HC, editor. Drug treatment of migraine and other headaches. Basel: Karger, 2000, 197-205
12. Diener HC, Limmroth V. Advances in the pharmacological treatment of migraine. Expert Opin Investig Drugs 2001; 10: 1831-45
13. Charlesworth B, Dowson A, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine. CNS Drugs 2003; 17 (9): 653-67
14. Lennox WG. Ergonovine versus ergotamine as a terminator of migraine headaches. Am J Med Sci 1938; 195: 458-68
15. Heyck H, Krayenbühl H. Der Kopfschmerz. Stuttgart: Thieme-Verlag, 1958
16. Limmroth V, May A, Diener HC. Parenteral acetylsalicylic acid and ergot derivatives in migraine attacks. Eur Neurol 1999; 44: 81-93
17. Stoll A, Hofmann A. Partialsynthese von Alkaloiden vom Typus des Ergobasins (6. Mitteilung uber Mutterkorn-alkaloide). Helv Chim Acta 1943; 26: 944-50
18. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine mesilate. Headache 1997; 37 Suppl. 1: S15-25
19. Lipton RB. Ergotamine tartrate and dihydroergotamine mesilate mesylate: safety profiles. Headache 1997; 37 Suppl. 1: S33-41
20. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine mesilate vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180-4
21. Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998; 6: 99-104
22. Visser WH, Ferrari MD, Bayliss EM, et al. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 1992; 12 (5): 308-13
23. Mathew NT, Dexter J, Couch J, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol 1992; 49 (12): 1271-6
24. Dahlöf C. Sumatriptan: pharmacological basis and clinical results. Curr Med Res Opin 2001; 17 Suppl. 1: 35-45
25. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-4
26. Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995; 45 Suppl. 7: S5-9
27. Yates R, Sorensen J, Bergstrom M, et al. Distribution and pharmacokinetics of zolmitriptan following administration by nasal spray [abstract]. Cephalalgia 2001; 21: 417
28. Yates R, Nairn K, Dixon R, et al. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharm 2002; 42: 1237-43
29. Nairn K, Kemp JV, Dane AL, et al. Evaluation of the effect of xylometazoline on the absorption of zolmitriptan nasal spray. Clin Drug Invest 2002; 22 (10): 703-7
30. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003; 17 (6): 431-47
31. Dowson A, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother 2002; 3 (7): 993-1005
32. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetic and efficacy. Drugs 2000; 60 (6): 1259-87
33. Sheftell FD, Fox AW. Acute migraine treatment outcome measures: a clinician's view. Cephalalgia 2000; 20 Suppl. 2: 14-24
34. Humbert H, Cabiac MD, Cubray C, et al. Human pharmacokinetics of dihydroergotamine mesilate administered by nasal spray. Clin Pharmacol Ther 1996; 60: 265-75
35. Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998; 55: 889-922
36. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358 (9294): 1668-75
37. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39 Suppl. 2: S20-6
38. Rapoport AM, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs 1997; 7: 37-46
39. Dahlöf C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999; 19: 769-78
40. Salonen R, Ashford E, Dahlöf C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 1994; 241: 463-9
41. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systemic review based on the number needed to treat. Cephalalgia 1998; 18: 532-8
42. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225-30
43. Dahlöf CG, Boes-Hansen S, Cederberg CG, et al. How does sumatriptan nasal spray perform in clinical practice? Cephalalgia 1998; 18: 278-82
44. Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine mesilate nasal spray in the acute treatment of migraine. Int J Clin Pract 2000; 54: 281-6
45. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine mesilate nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361-5
46. Tulunay FC, Karan O, Aydin N, et al. Dihydroergotamine nasal spray during migraine attacks: a double blind crossover study with placebo. Cephalalgia 1987; 7: 131-3
47. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44: 447-53
48. Mathew N. Dosing and administration of ergotamine tartrate and dihydroergotamine mesilate. Headache 1997; 37 Suppl. 1: S26-32
49. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983; 16: 695-9
50. Bertin L, Brion N, Farkkila M, et al. A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Int J Clin Pract 1999; 53 (8): 593-8
51. Tepper SJ, Cochran A, Hobbs S, et al., on behalf of the S2B351 Study Group. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998; 52: 31-5
52. Pfaffenrath V, Salonen R. Clinical efficacy and tolerability of sumatriptan suppository in the acute treatment of migraine: a review of data from clinical trials [abstract]. Eur J Neurol 1998; 5 Suppl. 3: S49
53. Crooks J, Stephen SA, Brass W. Clinical trial of inhaled ergotamine tartrate in migraine. BMJ 1964; 1: 221-4
54. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation (MAZE) survey. Headache 2003; 43: 19-26
55. Data on file. Harlow: GlaxoSmithKline, 2002
56. Bigal ME, Sheftell F, Rapoport AM, et al. Triptan use in a migraineur population: determinants of preference [abstract S22.0041. Neurology 2003; 60 Suppl. 1: A170
57. Dowson A, Charlesworth BC, Purdy A, et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003; 17 (11): 839-51
58. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8: Suppl. 7: 1-96
59. Dahlöf C. Clinical applications of new therapeutic deliveries in migraine. Neurology 2003; 61 (8 Suppl. 4): S31-4